ARSUF
Price
$20.03
Change
-$0.82 (-3.93%)
Updated
Oct 29 closing price
Capitalization
1.78B
BIOVF
Price
$28.97
Change
-$0.82 (-2.75%)
Updated
Aug 12 closing price
Capitalization
9.82B
Interact to see
Advertisement

ARSUF vs BIOVF

Header iconARSUF vs BIOVF Comparison
Open Charts ARSUF vs BIOVFBanner chart's image
Fagron SA
Price$20.03
Change-$0.82 (-3.93%)
Volume$425
Capitalization1.78B
Swedish Orphan Biovitrum AB
Price$28.97
Change-$0.82 (-2.75%)
Volume$500
Capitalization9.82B
ARSUF vs BIOVF Comparison Chart in %
Loading...
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARSUF vs. BIOVF commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARSUF is a Hold and BIOVF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (ARSUF: $20.03 vs. BIOVF: $28.97)
Brand notoriety: ARSUF and BIOVF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ARSUF: 100% vs. BIOVF: 159%
Market capitalization -- ARSUF: $1.78B vs. BIOVF: $9.82B
ARSUF [@Pharmaceuticals: Generic] is valued at $1.78B. BIOVF’s [@Pharmaceuticals: Generic] market capitalization is $9.82B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARSUF’s FA Score shows that 1 FA rating(s) are green whileBIOVF’s FA Score has 0 green FA rating(s).

  • ARSUF’s FA Score: 1 green, 4 red.
  • BIOVF’s FA Score: 0 green, 5 red.
According to our system of comparison, ARSUF is a better buy in the long-term than BIOVF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOVF’s TA Score shows that 3 TA indicator(s) are bullish.

  • BIOVF’s TA Score: 3 bullish, 3 bearish.

Price Growth

ARSUF (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while BIOVF (@Pharmaceuticals: Generic) price change was -2.75% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOVF($9.82B) has a higher market cap than ARSUF($1.78B). BIOVF has higher P/E ratio than ARSUF: BIOVF (21.90) vs ARSUF (17.97). BIOVF YTD gains are higher at: 4.736 vs. ARSUF (0.000). BIOVF has higher annual earnings (EBITDA): 9.77B vs. ARSUF (158M). BIOVF has more cash in the bank: 1.06B vs. ARSUF (116M). ARSUF has less debt than BIOVF: ARSUF (386M) vs BIOVF (12.8B). BIOVF has higher revenues than ARSUF: BIOVF (27B) vs ARSUF (872M).
ARSUFBIOVFARSUF / BIOVF
Capitalization1.78B9.82B18%
EBITDA158M9.77B2%
Gain YTD0.0004.736-
P/E Ratio17.9721.9082%
Revenue872M27B3%
Total Cash116M1.06B11%
Total Debt386M12.8B3%
FUNDAMENTALS RATINGS
ARSUF vs BIOVF: Fundamental Ratings
ARSUF
BIOVF
OUTLOOK RATING
1..100
4594
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
81
Overvalued
PROFIT vs RISK RATING
1..100
10064
SMR RATING
1..100
5765
PRICE GROWTH RATING
1..100
7258
P/E GROWTH RATING
1..100
4893
SEASONALITY SCORE
1..100
5545

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARSUF's Valuation (25) in the null industry is somewhat better than the same rating for BIOVF (81). This means that ARSUF’s stock grew somewhat faster than BIOVF’s over the last 12 months.

BIOVF's Profit vs Risk Rating (64) in the null industry is somewhat better than the same rating for ARSUF (100). This means that BIOVF’s stock grew somewhat faster than ARSUF’s over the last 12 months.

ARSUF's SMR Rating (57) in the null industry is in the same range as BIOVF (65). This means that ARSUF’s stock grew similarly to BIOVF’s over the last 12 months.

BIOVF's Price Growth Rating (58) in the null industry is in the same range as ARSUF (72). This means that BIOVF’s stock grew similarly to ARSUF’s over the last 12 months.

ARSUF's P/E Growth Rating (48) in the null industry is somewhat better than the same rating for BIOVF (93). This means that ARSUF’s stock grew somewhat faster than BIOVF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARSUFBIOVF
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
53%
Stochastic
ODDS (%)
N/A
Bullish Trend 3 days ago
49%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
54%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
47%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
20%
Bearish Trend 3 days ago
46%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
20%
Bearish Trend 3 days ago
42%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
59%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
43%
View a ticker or compare two or three
Interact to see
Advertisement
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
REZ81.960.49
+0.60%
iShares Residential & Multisector RE ETF
LIAV236.90N/A
N/A
LifeX 2061 Infl-Prt Longevity Inc ETF
SHY82.67-0.03
-0.04%
iShares 1-3 Year Treasury Bond ETF
IQM79.85-0.62
-0.77%
Franklin Intelligent Machines ETF
FNK54.14-0.45
-0.83%
First Trust Mid Cap Value AlphaDEX® ETF

ARSUF and

Correlation & Price change

A.I.dvisor tells us that ARSUF and GENPF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARSUF and GENPF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARSUF
1D Price
Change %
ARSUF100%
N/A
GENPF - ARSUF
23%
Poorly correlated
N/A
AVCNF - ARSUF
11%
Poorly correlated
-2.28%
ALID - ARSUF
8%
Poorly correlated
N/A
BOIRF - ARSUF
1%
Poorly correlated
N/A
BIOVF - ARSUF
1%
Poorly correlated
N/A
More

BIOVF and

Correlation & Price change

A.I.dvisor tells us that BIOVF and SFOSF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOVF and SFOSF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOVF
1D Price
Change %
BIOVF100%
N/A
SFOSF - BIOVF
21%
Poorly correlated
N/A
BIOYF - BIOVF
7%
Poorly correlated
-0.05%
BOIRF - BIOVF
1%
Poorly correlated
N/A
ARSUF - BIOVF
1%
Poorly correlated
N/A
BKUH - BIOVF
0%
Poorly correlated
N/A
More